The Psychotherapy in MDMA-Assisted Psychotherapy
Ioana Alina Cristea, Pim Cuijpers, Joar Øveraas Halvorsen
JAMA Psychiatry November 1, 2024 DOI: 10.1001/jamapsychiatry.2024.2887 (opens in new tab)
Summary
AI-generated from the abstractThe validity of clinical trials of MDMA-assisted psychotherapy for PTSD depends heavily on the quality of the psychotherapy component, which has been underappreciated in evaluations of the evidence. The authors argue that the psychotherapy itself must be carefully examined to properly interpret trial results and that its role is critical yet often overlooked.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Intervention | MDMA-assisted psychotherapy |
| Key finding | Argues that the psychotherapy component in MDMA-assisted psychotherapy trials for PTSD is a critical but overlooked factor in assessing trial validity. |
Abstract
This Viewpoint discusses the critical yet overlooked role of the psychotherapy component in assessing the validity of the trials of midomafetamine/3,4-methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress disorder.